Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

New Stock Coverage: Conatus Pharmaceuticals Is Not Only for Smart Scientists


Wall Street ratings agencies set the tone for today's stock market.

In honor of Alan Greenspan's 88th birthday, stocks celebrated with some of the erstwhile maestro's old-timey "irrational exuberance." Indeed, the utterly indecipherable former Fed head, known as the "Oracle of Delphi" when in office, even got a bonus present with Oracle (NYSE:ORCL) scoring a broker boost. To use a few $10 words his irresponsible asset bubble helped finance, the financial community used to abnegate Alan's bourgeois circumlocution. At least that's what it says in my dog-eared SparkNotes SAT dictionary, which I can mercifully now dispense with as they've just done away with the SAT essay. Far better SparkNotes than Spark Networks (NYSEMKT:LOV), which imploded 18.98% after incurring dual downgrades. The remarkable recent run of World Wrestling Entertainment (NYSE:WWE), which a modern-day Delphi Oracle predicted back in January, continued apace. It surged another 9.96% to take its 12-month increase to an astonishing 240.96%. Still think the sport is phony? Any pastime that unites the most improbable bedfellows on the planet -- the USA, Russia, and Iran -- is the real deal in my book. And worker productivity was surprisingly revised downward for the final few months of 2013. Fear not, however, for economic sages expect it to rebound this quarter. Really? Not if Warren Buffett has his way.
Today in economics, January consumer credit is expected to contract from the prior month's pace at 3:00 p.m. Eastern. On the corporate front, expect earnings announcements out of Big Lots (NYSE:BIG), Foot Locker (NYSE:FL), and Genesco (NYSE:GCO).
Conatus Pharmaceuticals (NASDAQ:CNAT): Roth Capital resumes Buy-rated research on the biotech.
Harman International (NYSE:HAR): Shares are assigned an Outperform at Raymond James, whose price objective is $125.
Jazz Pharmaceuticals (NASDAQ:JAZZ): Barclays begins the stock at Overweight. Its target price is an even $200.
Ladder Capital (NYSE:LADR): LADR is launched with a Buy rating, and unusually precise $22.25 target, at Deutsche Bank.
MGM Resorts (NYSE:MGM): Ascendiant Capital Markets covers the company at a Buy.
Regency Energy Partners (NYSE:RGP): The limited partnership gets picked up with a Hold at Deutsche, whose objective is $29.
Rouse Properties (NYSE:RSE): Bank of America-Merrill Lynch has a new neutral on the owner of regional malls, which fell 5.01% yesterday. (NYSE:CRM): Shares are started at a Neutral by boutique brokerage B. Riley & Co.
ServiceNow (NYSE:NOW): The stock is a Neutral, also at Riley.
Tallgrass Energy Partners (NYSE:TEP): Wells Fargo establishes an investment opinion of Outperform.
Thomson Reuters (NYSE:TRI): Deutsche Bank has a Hold on the financial news and information provider.

See also:

Stock Upgrades: Use Your Brain -- Buy Skullcandy

Stock Downgrades: Dumb Down CliffsNotes Owner Houghton Mifflin Harcourt
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos